NCT05085548View on ClinicalTrials.gov

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Advanced Pancreatic CancerSolid Tumor Malignancies
Interventions
DRUG

ProAgio Dose Levels (DL) 1,2,3

ProAgio is administered to study participants by intravenous injections once every 14 days.

DRUG

ProAgio Dose Levels (DL) 4,5,6

ProAgio is administered to study participants by intravenous injections once every 7 days.

DRUG

ProAgio Dose Levels 4a,5a,6a

ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.

Trial Locations (1)

20892

National Cancer Institute, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

ProDa BioTech, LLC

INDUSTRY